2-Nitrofluorene

2-Nitrofluorene

SCHEMBL29450702

O=[N+]([O-])c1ccc2c(c1)Cc1ccccc1-2

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.68
TLR9 Q9NR96 2/20 0.68
LMNA P02545 2/20 0.68
RAB9A P51151 2/20 0.68
MEN1 O00255 1/20 0.68
KMT2A Q03164 1/20 0.68
HSP90AA1 P07900 2/20 0.58
TDP2 O95551 1/20 0.55
CYP1A2 P05177 2/20 0.55
HSD17B10 Q99714 1/20 0.55
PTPRC P08575 3/20 0.54
ACHE P22303 2/20 0.54
S100A4 P26447 2/20 0.54
BCHE P06276 1/20 0.54
CES1 P23141 1/20 0.54
PARP1 P09874 2/20 0.52
GPR3 P46089 1/20 0.51
CRHBP P24387 1/20 0.51
CRHR2 Q13324 1/20 0.51
ALDH1A1 P00352 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Nitrofluorene SCHEMBL644332 1.00 MAPT (0.68) MAPTTLR9LMNARAB9AMEN1
2-Nitrofluorene SCHEMBL28186600 0.95 MAPT (0.62) MAPTTLR9LMNARAB9AMEN1
2-Nitrofluorene SCHEMBL28251179 0.94 MAPT (0.60) MAPTTLR9LMNARAB9AMEN1
SCHEMBL7618863 0.93 MAPT (0.58) MAPTTLR9LMNARAB9AMEN1
SCHEMBL12298162 0.92 PTPRC (0.58) MAPTTLR9LMNARAB9AMEN1
2-Nitrofluorene SCHEMBL8006385 0.91 MAPT (0.85) MAPTTLR9LMNARAB9AMEN1
SCHEMBL30049268 0.91 TLR9 (0.79) MAPTTLR9LMNARAB9AMEN1
SCHEMBL987760 0.91 TLR9 (0.79) MAPTTLR9LMNARAB9AMEN1
2-Nitrofluorene SCHEMBL7722767 0.89 MAPT (0.56) MAPTTLR9LMNARAB9AMEN1
2-Nitrofluorene SCHEMBL28029750 0.89 MAPT (0.56) MAPTTLR9LMNARAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624029-B2 JAK inhibitor compounds, method for synthesizing same and use thereof Galderma Holding SA (CH) 2026-05-12 US disclosed
US-12606559-B2 JAK inhibitor compounds, methods for synthesizing same and use thereof Galderma Holding SA (CH) 2026-04-21 US disclosed
US-12583868-B2 JAK inhibitors and methods for synthesizing and using thereof Galderma Holding SA (CH) 2026-03-24 US disclosed
US-20250304564-A1 NOVEL KV3 MODULATORS AUTIFONY THERAPEUTICS LTD (GB) 2025-10-02 US disclosed
US-20250268926-A1 METHOD AND COMPOSITION FOR TREATING, ALLEVIATING OR PREVENTING A DISEASE OR CONDITION CAUSED BY AIR POLLUTANT HONG KONG BAPTIST UNIVERSITY (CN) 2025-08-28 US disclosed
US-20250263376-A1 (E)-N-CINNAMOYLAMINOALKANOLS WITH MELANOGENESIS INHIBITORY ACTIVITY UNIWERSYTET JAGIELLONSKI (PL) 2025-08-21 US disclosed
US-12358901-B2 KV3 modulators AUTIFONY THERAPEUTICS LIMITED (GB) 2025-07-15 US disclosed
EP-3883563-B1 CANNABIDIOL-TYPE CANNABINOID COMPOUND JAZZ PHARMACEUTICALS RESEARCH UK LTD (GB) 2025-04-30 EP disclosed
US-20250129041-A1 MOLECULAR GLUE AND USES THEREOF ASTROGEN, INC. (KR) 2025-04-24 US disclosed
WO-2025084740-A1 NOVEL MOLECULAR ADHESIVE AND USE THEREOF 주식회사 아스트로젠 2025-04-24 WO disclosed
EP-4185587-A1 COMPOUNDS USEFUL AS FACTOR XIA INHIBITORS JANSSEN Pharmaceutica NV (BE) 2023-05-31 EP disclosed
US-20220383550-A1 METHOD FOR ASSESSING ASSESSMENT TARGETS, IMAGE PROCESSING DEVICE, SYSTEM FOR ASSESSING ASSESSMENT TARGETS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2022-12-01 US disclosed
WO-2022223480-A1 GREEN SOLVENTS FOR CHEMICAL REACTIONS ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2022-10-27 WO disclosed
EP-4056672-A1 METHOD FOR ASSESSING ASSESSMENT TARGETS, IMAGE PROCESSING DEVICE, SYSTEM FOR ASSESSING ASSESSMENT TARGETS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2022-09-14 EP disclosed
CN-114324681-A High-throughput method for detecting content of nitro polycyclic aromatic hydrocarbon 南通市疾病预防控制中心 2022-04-12 CN disclosed
WO-2022072975-A1 COMPOSITIONS AND METHODS OF TREATMENT FOR SARS-COV-2 THROUGH PAPAIN PROTEASE INHIBITION UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2022-04-07 WO disclosed
US-20220087992-A1 COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-24 US disclosed
WO-2022054005-A1 NOVEL JAK INHIBITOR COMPOUNDS, METHOD FOR SYNTHESIZING SAME AND USE THEREOF Galderma Holding SA (CH) 2022-03-17 WO disclosed
WO-2022054006-A1 NOVEL JAK INHIBITOR COMPOUNDS, METHOD FOR SYNTHESIZING SAME AND USE THEREOF Galderma Holding SA (CH) 2022-03-17 WO disclosed
WO-2022053931-A1 NOVEL JAK INHIBITOR COMPOUNDS, METHOD FOR SYNTHESIZING SAME AND USE THEREOF Galderma Holding SA (CH) 2022-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358901-B2 KV3 modulators KCNN3, KCNA3, KCNH3 MAPT 4712/4885TLR9 3197/4885LMNA 1599/4885
US-20220087992-A1 COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION ALDH1A2, PDE6D, PDE6C MAPT 745/4885TLR9 3454/4885LMNA 884/4885
US-20250263376-A1 (E)-N-CINNAMOYLAMINOALKANOLS WITH MELANOGENESIS INHIBITORY ACTIVITY TYR, MITF, MC1R MAPT 4655/4885TLR9 4525/4885LMNA 1056/4885
US-20250129041-A1 MOLECULAR GLUE AND USES THEREOF ILK, FGB, UNC119 MAPT 655/4885TLR9 3652/4885LMNA 3193/4885
US-12606559-B2 JAK inhibitor compounds, methods for synthesizing same and use thereof JAK2, JAK1, JAK3 MAPT 4442/4885TLR9 1280/4885LMNA 3990/4885
US-12624029-B2 JAK inhibitor compounds, method for synthesizing same and use thereof JAK2, JAK1, JAK3 MAPT 4257/4885TLR9 1796/4885LMNA 4367/4885
US-12583868-B2 JAK inhibitors and methods for synthesizing and using thereof JAK2, JAK1, JAK3 MAPT 4346/4885TLR9 1699/4885LMNA 4003/4885
US-20250304564-A1 NOVEL KV3 MODULATORS KCNN3, KCNA3, KCND3 MAPT 4634/4885TLR9 3978/4885LMNA 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.